Key facts
- Huihe Healthcare’s last known valuation is $1.1B (Dec 2025).
- It has raised $69.7M; the latest was Later Stage VC in Dec 2025.
- Notable investors include Suzhou Oriza Holdings Corporation, IDG Capital, Legend Star, Guotai Junan Innovation Investment, SDIC Unity Capital — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Huihe Healthcare
- ·The full record, as it builds
Funding rounds
No funding rounds for Huihe Healthcare are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Huihe Healthcare
Manufacturer of intervention medical devices intended for structural heart disease. The company is engaged in the research and development of medical devices specifically for heart diseases, such as the tricuspid valve repair system, providing patients with heart diseases with effective medical solutions.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2019
- Employees
- 16
- Ownership
- Privately Held (backing)
Huihe Healthcare doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Huihe Healthcare shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Huihe Healthcare in its N-PORT filings yet. We sweep new filings monthly.